Back to results
US 9,789,171 B2Granted
Anti-fugetactic agents for the treatment of ovarian cancer
AssigneeThe General Hospital Corporation
InventorsMark C. Poznansky, John T. Potts, Jr., Fabrizio Vianello, Natalia Papeta
Life of this patent
Estimating the term…
Abstract
This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response.
Claims6
A method for increasing the migratory capacity of immune cells into a mammalian ovarian tumor exhibiting fugetactic activity on said immune cells due to CXCL12 secretion, wherein said immune cells comprise tumor antigen-specific T-cells, which method comprises:
- a) selecting a mammal having said tumor which secretes a fugetactic effective amount of CXCL12 around said tumor wherein said concentration of CXCL12 is greater than 100 nM;
- b) contacting said T-cells with an anti-fugetactic concentration of 1,1′-[1,4-phenylenebis-(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] of from 0.08 μg/mL up to 5 μg/mL wherein said T-cells are now capable of increasing their migration into said tumor through the fugetactic activity of said tumor.
Dependencies are inferred from the claim text.